Additionally, Kaplan-Meier analysis of progression-free survival (PFS) revealed that high expression of LOX-1 was associated with shorter progression-free survival in CRC patients (P < 0.05; Fig. 2B). This evidence concerns the gene OLR1 and colorectal carcinoma.